Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ID-Specific Donor Vaccinated Lymphocyte Infusion for Myeloma
NCT01174082Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2010
- Primary completion
- Feb 2017
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of Autologous FL vaccine in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2010; status: terminated.
02
Drugs
Autologous FL vaccine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01174082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01174082.